Squarepoint Ops LLC Purchases Shares of 21,682 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Squarepoint Ops LLC acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,682 shares of the company's stock, valued at approximately $897,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its position in shares of Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after buying an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $35,000. AlphaQuest LLC lifted its holdings in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after acquiring an additional 1,658 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in Mirum Pharmaceuticals by 8.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after acquiring an additional 312 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Mirum Pharmaceuticals by 260.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,112 shares of the company's stock valued at $211,000 after purchasing an additional 3,694 shares during the last quarter.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock traded down $0.68 during mid-day trading on Tuesday, hitting $45.29. 457,345 shares of the company's stock traded hands, compared to its average volume of 519,746. Mirum Pharmaceuticals, Inc. has a one year low of $23.99 and a one year high of $54.23. The company has a market cap of $2.24 billion, a PE ratio of -22.42 and a beta of 0.95. The firm has a 50 day moving average price of $42.62 and a 200 day moving average price of $44.68. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The business had revenue of $111.59 million for the quarter, compared to analysts' expectations of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company's revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.54) earnings per share. On average, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MIRM. Raymond James reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and issued a $73.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Finally, JMP Securities boosted their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a report on Friday, May 9th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of "Buy" and an average target price of $60.73.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 27,279 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at $6,129,318.61. This represents a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jolanda Howe sold 57,606 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the transaction, the senior vice president now directly owns 4,841 shares of the company's stock, valued at approximately $214,698.35. The trade was a 92.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,764 shares of company stock valued at $4,109,161. Company insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.